Century Therapeutics, Inc. (IPSC)
2.11
+0.02
(+0.96%)
USD |
NASDAQ |
Sep 04, 16:00
2.115
0.00 (0.00%)
After-Hours: 20:00
Century Therapeutics Research and Development Expense (Quarterly) : 16.98M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 16.98M |
| March 31, 2026 | 14.10M |
| December 31, 2025 | 16.14M |
| September 30, 2025 | 19.40M |
| June 30, 2025 | 23.66M |
| March 31, 2025 | 23.36M |
| December 31, 2024 | 26.06M |
| September 30, 2024 | 23.93M |
| June 30, 2024 | 23.76M |
| March 31, 2024 | 20.20M |
| December 31, 2023 | 22.30M |
| September 30, 2023 | 22.79M |
| June 30, 2023 | 22.73M |
| Date | Value |
|---|---|
| March 31, 2023 | 24.90M |
| December 31, 2022 | 25.58M |
| September 30, 2022 | 25.90M |
| June 30, 2022 | 24.49M |
| March 31, 2022 | 21.20M |
| December 31, 2021 | 21.80M |
| September 30, 2021 | 19.54M |
| June 30, 2021 | 18.93M |
| March 31, 2021 | 15.37M |
| December 31, 2020 | 12.44M |
| September 30, 2020 | 10.81M |
| June 30, 2020 | 8.484M |
| March 31, 2020 | 7.943M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Tenax Therapeutics, Inc. | 12.85M |
| Exicure, Inc. | 0.174M |
| Absci Corp. | 22.62M |
| Celularity, Inc. | 1.92M |
| Cardio Diagnostics Holdings, Inc. | 0.1629M |